Financings Of The Fortnight: Too Soon To Size Up Impact Of The U.S. JOBS Act
This article was originally published in The Pink Sheet Daily
Plus news on recent financings by Onyx Therapeutics, InterMune, Versartis and Aileron Therapeutics.
You may also be interested in...
Now focused on two key programs in its osteoarthritis portfolio, the Massachusetts drug developer will align itself for a more traditional exit rather than a Big Pharma partnership.
Onyx is pricing new myeloma drug carfilzomib at $9,950 per cycle, 65% higher than Takeda/Millennium’s pioneering proteasome inhibitor Velcade. Launch plans include financial assistance for providers, comprehensive patient assistance program and transition for expanded access patients to commercial drug.
In the latest in “The Pink Sheet”’s market snapshot series, InterMune continues to work on getting pirfenidone approved in the U.S., while several companies are developing next-stage therapies for IPF.